Trial Profile
Phase 1 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; VE 800 (Primary) ; Vancomycin
- Indications Adenocarcinoma; Colorectal cancer; Gastric cancer; Malignant melanoma; Oesophageal cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms Consortium-IO
- Sponsors Vedanta Biosciences
- 16 Mar 2023 Status changed from active, no longer recruiting to completed.
- 21 Jul 2021 According to a Vedanta Biosciences media release, company is nearing completion of Stage 1 of this trial, and also plans to present the results at a future medical conference.
- 22 Jun 2021 Planned End Date changed from 1 Jul 2022 to 1 Aug 2022.